U01CA232758
Cooperative Agreement
Overview
Grant Description
B cell-dependent anti-tumor immunity in ovarian cancer.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Durham,
North Carolina
27710
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/23 to 01/31/24 and the total obligations have increased 408% from $781,585 to $3,974,357.
Duke University was awarded
B cell-dependent anti-tumor immunity in ovarian cancer
Cooperative Agreement U01CA232758
worth $3,974,357
from National Cancer Institute in September 2018 with work to be completed primarily in Durham North Carolina United States.
The grant
has a duration of 5 years 4 months and
was awarded through assistance program 93.353 21st Century Cures Act - Beau Biden Cancer Moonshot.
The Cooperative Agreement was awarded through grant opportunity Change of Recipient Organization (Type 7 Parent Clinical Trial Optional).
Status
(Complete)
Last Modified 5/20/24
Period of Performance
9/20/18
Start Date
1/31/24
End Date
Funding Split
$4.0M
Federal Obligation
$0.0
Non-Federal Obligation
$4.0M
Total Obligated
Activity Timeline
Transaction History
Modifications to U01CA232758
Additional Detail
Award ID FAIN
U01CA232758
SAI Number
U01CA232758-498108502
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
TP7EK8DZV6N5
Awardee CAGE
4B478
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $4,656,676 | 100% |
Modified: 5/20/24